Plain-English translation of NCT06649253 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are trying to understand why some children with acute lymphoblastic leukemia (a common childhood blood cancer) get sick again after treatment, even though treatments have improved significantly. This study focuses on a protein called CD9 that may help cancer cells hide and survive in protected areas of the body. By studying blood and bone marrow samples from children at diagnosis, during treatment, and if relapse happens, researchers hope to find new ways to predict and prevent relapses.
About 1 in 5 children with this type of leukemia experience a relapse despite better treatments. Understanding how CD9 works could help doctors identify which children are at higher risk and develop new ways to stop cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You will have blood and bone marrow samples collected at three key moments: when you are first diagnosed, after your first round of treatment, and if a relapse occurs. These samples will be analyzed in the laboratory to study the genes and proteins involved in relapse. The study does not involve taking any new medication — it is purely a research study to help doctors better understand this disease.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France